List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9319301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endoscopic Papillectomy for Ampullary Adenomas: Different Outcomes in Sporadic Tumors and Those Associated with Familial Adenomatous Polyposis. Journal of Gastrointestinal Surgery, 2021, 25, 457-466.	1.7	7
2	Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement. Digestive and Liver Disease, 2021, 53, 409-417.	0.9	9
3	Risk of colorectal polyps and of malignancies in asymptomatic carriers of mutations in the main DNA mismatch repair genes. Scandinavian Journal of Gastroenterology, 2018, 53, 31-37.	1.5	2
4	Attenuated polyposis of the large bowel: a morphologic and molecular approach. Familial Cancer, 2017, 16, 211-220.	1.9	6
5	Clinical features of colorectal cancer patients in advanced age: a population-based approach. Internal and Emergency Medicine, 2016, 11, 191-197.	2.0	8
6	Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clinical Epigenetics, 2015, 7, 131.	4.1	45
7	The perception of health-related quality of life in colon cancer patients during chemotherapy: differences between men and women. Internal and Emergency Medicine, 2015, 10, 423-429.	2.0	9
8	Involvement of <i>MBD4</i> inactivation in mismatch repair-deficient tumorigenesis. Oncotarget, 2015, 6, 42892-42904.	1.8	43
9	<i>MLH1</i> constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. Epigenetics, 2014, 9, 1431-1438.	2.7	22
10	Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Internal and Emergency Medicine, 2014, 9, 151-160.	2.0	29
11	Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors. Techniques in Coloproctology, 2014, 18, 285-289.	1.8	11
12	Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	10.7	1,554
13	Disease presentation, treatment and survival for Italian colorectal cancer patients: a EUROCARE high resolution study. European Journal of Public Health, 2014, 24, 98-100.	0.3	5
14	What clinicians wish to know about benign colorectal polyps: An operative classification. Pathology Research and Practice, 2014, 210, 645-648.	2.3	1
15	An unusual case of familial adenomatous polyposis with very early symptom occurrence. Familial Cancer, 2014, 13, 375-380.	1.9	3
16	MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. European Journal of Human Genetics, 2014, 22, 923-929.	2.8	39
17	Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis. Oncology Reports, 2014, 31, 103-110.	2.6	13
18	Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1303-1310.	2.5	33

#	Article	IF	CITATIONS
19	Incidence, clinical features and possible etiology of early onset (≤0Âyears) colorectal neoplasms. Internal and Emergency Medicine, 2013, 9, 623-31.	2.0	6
20	Incidence trend of malignant polyps through the data of a specialized colorectal cancer registry: clinical features and effect of screening. Scandinavian Journal of Gastroenterology, 2013, 48, 1294-1301.	1.5	13
21	Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.	12.1	630
22	Colonoscopic surveillance of first-degree relatives of colorectal cancer patients in a faecal occult blood screening programme. Cancer Epidemiology, 2013, 37, 469-473.	1.9	3
23	Cancer risk associated with STK11/LKB1 germline mutations in Peutz–Jeghers syndrome patients: Results of an Italian multicenter study. Digestive and Liver Disease, 2013, 45, 606-611.	0.9	113
24	Duodenal carcinoma in a 37-year-old man with Cowden/Bannayan syndrome. Digestive and Liver Disease, 2013, 45, 75-78.	0.9	9
25	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. Techniques in Coloproctology, 2013, 17, 79-87.	1.8	12
26	A case of pneumatosis cystoides intestinalis mimicking familial adenomatous polyposis. Familial Cancer, 2013, 12, 573-576.	1.9	3
27	Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study. Acta Oncológica, 2013, 52, 1682-1690.	1.8	13
28	Th Inducing POZ-Kruppel Factor (ThPOK) Is a Key Regulator of the Immune Response since the Early Steps of Colorectal Carcinogenesis. PLoS ONE, 2013, 8, e54488.	2.5	8
29	PLZF Expression during Colorectal Cancer Development and in Normal Colorectal Mucosa according to Body Size, as Marker of Colorectal Cancer Risk. Scientific World Journal, The, 2013, 2013, 1-9.	2.1	14
30	Estimates of cancer burden in Emilia-Romagna. Tumori, 2013, 99, 327-33.	1.1	0
31	Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scandinavian Journal of Gastroenterology, 2012, 47, 1211-1217.	1.5	21
32	Immunohistochemical Assessment of Lymphovascular Invasion in Stage I Colorectal Carcinoma. American Journal of Surgical Pathology, 2012, 36, 66-72.	3.7	58
33	Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. International Journal of Oncology, 2012, 41, 260-6.	3.3	14
34	Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 621-628.	2.8	69
35	MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers. Clinical Cancer Research, 2012, 18, 3142-3153.	7.0	21
36	Identification of Lynch Syndrome Among Patients With Colorectal Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 1555.	7.4	443

#	Article	IF	CITATIONS
37	Regional inequalities in cancer care persist in Italy and can influence survival. Cancer Epidemiology, 2012, 36, 541-547.	1.9	26
38	Looking at Differences in Stage and Treatment of Colorectal Cancers across Italy: A EUROCARE-5 High Resolution Study. Tumori, 2012, 98, 671-677.	1.1	3
39	Clinical and molecular characterization of colorectal cancer in young Moroccan patients. Turkish Journal of Gastroenterology, 2012, 23, 686-690.	1.1	5
40	Looking at differences in stage and treatment of colorectal cancers across Italy: a EUROCARE-5 high resolution study. Tumori, 2012, 98, 671-7.	1.1	1
41	Lymph node micrometastasis and survival of patients with Stage I (Dukes' A) colorectal carcinoma. Scandinavian Journal of Gastroenterology, 2011, 46, 881-886.	1.5	22
42	Neutrophil gelatinase–associated lipocalin: a new prognostic marker in stage I colorectal carcinoma?. Human Pathology, 2011, 42, 1720-1726.	2.0	9
43	Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathology Research and Practice, 2011, 207, 479-486.	2.3	24
44	What should we advise about alcohol consumption. Internal and Emergency Medicine, 2011, 6, 87-87.	2.0	3
45	Long-term survey of patients with curable colorectal cancer with specific reference to the quality of life. Internal and Emergency Medicine, 2011, 6, 529-535.	2.0	14
46	Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. Cancer, 2011, 117, 4325-4335.	4.1	12
47	Surgical management of the duodenal manifestations of familial adenomatous polyposis. British Journal of Surgery, 2011, 98, 480-484.	0.3	36
48	Lymphatic vessel density and its prognostic value in stage I colorectal carcinoma. Journal of Clinical Pathology, 2011, 64, 6-12.	2.0	24
49	Integrated analysis of unclassified variants in mismatch repair genes. Genetics in Medicine, 2011, 13, 115-124.	2.4	34
50	Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 11-19.	2.8	23
51	Infliximab-related hepatitis: discussion of a case and review of the literature. Internal and Emergency Medicine, 2010, 5, 193-200.	2.0	105
52	Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Familial Cancer, 2010, 9, 109-115.	1.9	103
53	Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Familial Cancer, 2010, 9, 365-376.	1.9	10
54	Clinical features and colorectal cancer survival: An attempt to explain differences between two different Italian regions. European Journal of Cancer, 2010, 46, 142-149.	2.8	13

#	Article	IF	CITATIONS
55	Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut, 2010, 59, 975-986.	12.1	635
56	Prognostic Relevance of MLH1 and MSH2 Mutations in Hereditary Non-Polyposis Colorectal Cancer Patients. Tumori, 2009, 95, 731-738.	1.1	8
57	Differentiated Thyroid Carcinoma (DTC) in a Young Woman with Peutz-Jeghers Syndrome: Are these Two Conditions Associated?. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 234-239.	1.2	12
58	Survival, surgical management and perioperative mortality of colorectal cancer in the 21-year experience of a specialised registry. International Journal of Colorectal Disease, 2009, 24, 777-788.	2.2	9
59	Attitude of the Italian general population towards prevention and screening of the most common tumors, with special emphasis on colorectal malignancies. Internal and Emergency Medicine, 2009, 4, 213-220.	2.0	13
60	Cyclooxygenase-2 and Hypoxia-Inducible Factor- $1\hat{l}$ + protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Letters, 2009, 279, 221-229.	7.2	57
61	Relative role of <i>APC</i> and <i>MUTYH</i> mutations in the pathogenesis of familial adenomatous polyposis. Scandinavian Journal of Gastroenterology, 2009, 44, 1092-1100.	1.5	17
62	Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut, 2008, 57, 704-713.	12.1	591
63	Myeloperoxidase-Positive Cell Infiltration in Colorectal Carcinogenesis as Indicator of Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2291-2297.	2.5	83
64	Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 746-753.	1.5	10
65	O6-methylguanine-DNA methyltransferase promoter hypermethylation in colorectal carcinogenesis. Oncology Reports, 2007, 17, 1421.	2.6	5
66	Mismatch Repair Gene Mutations in Iranian HNPCC Families. American Journal of Gastroenterology, 2007, 102, S559.	0.4	0
67	Frequency of constitutional <i>MSH6 </i> mutations in a consecutive series of families with clinical suspicion of HNPCC. Clinical Genetics, 2007, 72, 230-237.	2.0	16
68	Identification and Classification of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome): Adapting Old Concepts to Recent Advancements. Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group. Diseases of the Colon and Rectum, 2007, 50, 2126-2134.	1.3	12
69	Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. Internal and Emergency Medicine, 2007, 2, 269-279.	2.0	27
70	Survival from rare cancer in adults: a population-based study. Lancet Oncology, The, 2006, 7, 132-140.	10.7	120
71	Immunohistochemical Expression of MYH Protein Can Be Used to Identify Patients With MYH-Associated Polyposis. Gastroenterology, 2006, 131, 439-444.	1.3	24
72	Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathology Research and Practice, 2006, 202, 663-670.	2.3	43

#	Article	IF	CITATIONS
73	Impact of Surgery on the Development of Duodenal Cancer in Patients with Familial Adenomatous Polyposis. Diseases of the Colon and Rectum, 2006, 49, 1860-1866.	1.3	4
74	Whipple's disease in a father-son pair. Internal and Emergency Medicine, 2006, 1, 254-256.	2.0	13
75	Adjuvant Chemotherapy in Colorectal Cancer Patients with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 3866-3867.	7.0	2
76	The obesity epidemic. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 234-234.	0.5	1
77	Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clinical Genetics, 2005, 68, 442-447.	2.0	76
78	Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. British Journal of Dermatology, 2005, 152, 1335-1338.	1.5	31
79	Identification of Muir–Torre syndrome among patients with sebaceous tumors and keratoacanthomas. Cancer, 2005, 103, 1018-1025.	4.1	136
80	Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. International Journal of Colorectal Disease, 2005, 20, 147-154.	2.2	20
81	Investigation of APC Mutations in a Turkish Familial Adenomatous Polyposis Family by Heterodublex Analysis. Diseases of the Colon and Rectum, 2005, 48, 567-571.	1.3	3
82	Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut, 2005, 54, 268-273.	12.1	114
83	Molecular Genetic Alterations and Clinical Features in Early-Onset Colorectal Carcinomas and Their Role for the Recognition of Hereditary Cancer Syndromes. American Journal of Gastroenterology, 2005, 100, 2280-2287.	0.4	66
84	Microsatellite Instability and Colorectal Cancer Prognosis. Clinical Cancer Research, 2005, 11, 8332-8340.	7.0	339
85	Muir-Torre syndrome. Lancet Oncology, The, 2005, 6, 980-987.	10.7	266
86	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Annals of Oncology, 2004, 15, 1136-1142.	1.2	22
87	Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. Annals of Oncology, 2004, 15, 940-946.	1.2	56
88	A founder MLH1 mutation in families from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal cancer associated with protein elongation and instability. Journal of Medical Genetics, 2004, 41, 34e-34.	3.2	22
89	Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. British Journal of Cancer, 2004, 90, 882-887.	6.4	57
90	Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the <i>MYH</i> gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. International Journal of Cancer, 2004, 109, 680-684.	5.1	159

#	Article	IF	CITATIONS
91	Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas. Pathology Research and Practice, 2004, 200, 371-377.	2.3	26
92	EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Annals of Oncology, 2003, 14, v61-v118.	1.2	638
93	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 2003, 14, v128-v149.	1.2	400
94	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Annals of Oncology, 2003, 14, v14-v27.	1.2	74
95	Cancer prevalence in European registry areas. Annals of Oncology, 2002, 13, 840-865.	1.2	164
96	Measuring cancer prevalence in Europe: the EUROPREVAL Project. Annals of Oncology, 2002, 13, 831-839.	1.2	88
97	Different molecular mechanisms underlie genomic deletions in theMLH1 Gene. Human Mutation, 2002, 20, 368-374.	2.5	34
98	Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. International Journal of Colorectal Disease, 2002, 17, 109-114.	2.2	78
99	Hereditary Non-polyposis Colorectal Cancer (Lynch Syndrome). , 2002, , 191-224.		2
100	The Causes of Colorectal Cancer. , 2002, , 1-22.		0
101	Familial Adenomatous Polyposis. , 2002, , 225-251.		0
102	Pathogenesis of Colorectal Cancer. , 2002, , 23-48.		0
103	Other Polyposis of the Large Bowel. , 2002, , 253-274.		0
104	Survival and Follow-up of Colorectal Cancer. , 2002, , 163-179.		0
105	Pathology of Colorectal Cancer. , 2002, , 49-78.		0
106	Colorectal Cancer Screening and Surveillance. , 2002, , 95-115.		0
107	Prevention and Chemoprevention of Colorectal Neoplasms. , 2002, , 117-133.		0
108	Molecular Screening for Hereditary Nonpolyposis Colorectal Cancer: A Prospective, Population-Based Study. Journal of Clinical Oncology, 2001, 19, 3944-3950.	1.6	101

#	Article	IF	CITATIONS
109	Phenotype-genotype correlations in an extended family with adenomatosis coli and an unusual APC gene mutation. Diseases of the Colon and Rectum, 2001, 44, 1597-1604.	1.3	9
110	Methylation pattern of different regions of theMLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes and Cancer, 2001, 31, 357-361.	2.8	53
111	Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Familial Cancer, 2001, 1, 95-101.	1.9	24
112	Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2001, 95, 323-328.	5.1	19
113	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts. , 2000, 27, 424-429.		19
114	Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut, 2000, 47, 533-538.	12.1	234
115	Problems in the identification of hereditary nonpolyposis colorectal cancer in two families with late development of full-blown clinical spectrum. American Journal of Gastroenterology, 2000, 95, 2110-2115.	0.4	2
116	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts. Genes Chromosomes and Cancer, 2000, 27, 424-429.	2.8	1
117	The Prevalence of Colorectal Cancer in Italy. Tumori, 1999, 85, 387-390.	1.1	7
118	Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2. European Journal of Human Genetics, 1999, 7, 778-782.	2.8	31
119	Variations in survival for invasive cervical cancer among European women, 1978-89. EUROCARE Working Group. Cancer Causes and Control, 1999, 10, 575-581.	1.8	21
120	Suspected hereditary nonpolyposis colorectal cancer. Diseases of the Colon and Rectum, 1999, 42, 710-715.	1.3	93
121	Microsatellite instability in multiple colorectal tumors. International Journal of Cancer, 1999, 81, 1-5.	5.1	72
122	Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene, 1998, 17, 157-163.	5.9	68
123	310 basepair APC deletion with duplication of breakpoint (4394ins 15del310) in an Italian polyposis patient. Human Mutation, 1998, 11, S220-S222.	2.5	12
124	MLH1 and MSH2 constitutinal mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. , 1998, 75, 835-839.		50
125	Survival of colorectal cancer patients in Europe during the period 1978–1989. European Journal of Cancer, 1998, 34, 2176-2183.	2.8	133
126	The EUROCARE II study. European Journal of Cancer, 1998, 34, 2139-2153.	2.8	61

#	Article	IF	CITATIONS
127	Small bowel carcinoma in hereditary nonpolyposis colorectal cancer. American Journal of Gastroenterology, 1998, 93, 2219-2222.	0.4	15
128	Hereditary Nonpolyposis Colorectal Cancer: An Approach to the Selection of Candidates to Genetic TestingBased on Clinical and MolecularCharacteristics. Public Health Genomics, 1998, 1, 229-236.	1.0	10
129	Aberrant crypt foci in patients with colorectal cancer. British Journal of Cancer, 1998, 77, 2343-2348.	6.4	53
130	Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 1997, 113, 1146-1158.	1.3	682
131	Cancer Patient Survival in the Elderly in Italy. Tumori, 1997, 83, 490-496.	1.1	23
132	Survival in Adult Italian Cancer Patients, 1978–1989. Tumori, 1997, 83, 39-425.	1.1	28
133	Variations in the Survival of Adult Cancer Patients in Italy. Tumori, 1997, 83, 497-504.	1.1	28
134	Recommendations for Clinical Management of Familial Adenomatous Polyposis. Tumori, 1997, 83, 800-803.	1.1	1
135	Histology of aberrant crypt foci in the human colon. Histopathology, 1997, 30, 328-334.	2.9	73
136	Characterization ofMSH2 andMLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer. , 1997, 18, 8-18.		67
137	K-ras andp53 mutations in hereditary non-polyposis colorectal cancers. International Journal of Cancer, 1997, 74, 94-96.	5.1	80
138	Survival analysis in families affected by hereditary non-polyposis colorectal cancer. , 1997, 71, 373-376.		50
139	Survival for colon and rectal cancer in a population-based cancer registry. European Journal of Cancer, 1996, 32, 295-302.	2.8	82
140	Clinical features, frequency and prognosis of Dukes' A colorectal carcinoma: A population-based investigation. European Journal of Cancer, 1996, 32, 1957-1962.	2.8	15
141	Inheritance and susceptibility to tumours of the large bowel: A new classification of colorectal malignancies. European Journal of Cancer, 1996, 32, 2206-2211.	2.8	7
142	Descriptive Epidemiology of Hereditary Non-Polyposis Colorectal Cancer. Tumori, 1996, 82, 102-106.	1.1	15
143	High prevalence of adenomas and microadenomas of the duodenal papilla and periampullary region in patients with familial adenomatous polyposis. European Journal of Gastroenterology and Hepatology, 1996, 8, 1201-1206.	1.6	47
144	Hereditary nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and counseling aspects. , 1996, 62, 353-364.		79

#	Article	IF	CITATIONS
145	K-ras AND p53 MUTATIONS IN HUMAN COLORECTAL ABERRANT CRYPT FOCI. Journal of Pathology, 1996, 178, 259-263.	4.5	57
146	Frequency and clinical features of multiple tumors of the large bowel in the general population and in patients with hereditary colorectal carcinoma. Cancer, 1996, 77, 2013-2021.	4.1	61
147	The effect of family size on estimates of the frequency of hereditary non-polyposis colorectal cancer. British Journal of Cancer, 1995, 72, 1320-1323.	6.4	25
148	Biologic Characterization of Hereditary Non-Polyposis Colorectal Cancer: <i>Nuclear Ploidy, AgNOR Count, Microvessel Distribution, Oncogene Expression, and Grade-Related Parameters</i> . American Journal of Clinical Pathology, 1995, 103, 265-270.	0.7	28
149	Argyrophilic nucleolar organizer regions and bromodeoxyuridine and3[H]-thymidine labelling indices in colorectal cancer. Cell Proliferation, 1995, 28, 471-480.	5.3	1
150	Risk of cancer revealed by follow-up of families with hereditary non-polyposis colorectal cancer: Reply to Dr. Eluf-Neto. International Journal of Cancer, 1995, 61, 744-744.	5.1	0
151	Familial aggregation of tumors and detection of hereditary non-polyposis colorectal cancer in 3-year experience of 2 population-based colorectal-cancer registries. International Journal of Cancer, 1995, 62, 685-690.	5.1	22
152	Comparisons of colon–cancer survival among european countries: The eurocare study. International Journal of Cancer, 1995, 63, 43-48.	5.1	64
153	First observation of microadenomas in the ileal mucosa of patients with familial adenomatous polyposis and colectomies. Gastroenterology, 1995, 109, 374-380.	1.3	22
154	Clinical and Biologic Features of Adenomatosis Coli in Northern Italy. Scandinavian Journal of Gastroenterology, 1995, 30, 771-779.	1.5	14
155	Prevalence of Hereditary Nonpolyposis Colorectal Carcinoma (HNPCC). Annals of Medicine, 1994, 26, 209-214.	3.8	24
156	Role of clinical criteria in the diagnosis of hereditary non-polyposis colorectal cancer (HNPCC): Results of a multivariate analysis. International Journal of Cancer, 1994, 58, 799-802.	5.1	19
157	Genetic epidemiology of hereditary non-polyposis colorectal cancer syndromes in Modena, Italy: results of a complex segregation analysis. Annals of Human Genetics, 1994, 58, 275-295.	0.8	23
158	Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry. Cancer, 1993, 71, 3493-3501.	4.1	109
159	Tumour spectrum in hereditary non-polyposis colorectal cancer (HNPCC) and in families with "suspected hnpcc― A population-based study in northern Italy. International Journal of Cancer, 1993, 54, 371-377.	5.1	73
160	Risk of cancer revealed by follow-up of families with hereditary non-polyposis colorectal cancer: A population-based study. International Journal of Cancer, 1993, 55, 202-207.	5.1	22
161	Linkage studies in Italian families with familial adenomatous polyposis. Human Genetics, 1993, 90, 545-550.	3.8	4
162	Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Diseases of the Colon and Rectum, 1993, 36, 227-234.	1.3	141

#	Article	IF	CITATIONS
163	Descriptive epidemiology of colorectal cancer in Italy: The 6-year experience of a specialised registry. European Journal of Cancer, 1993, 29, 367-371.	2.8	36
164	Generalized juvenile polyposis with mixed pattern and gastric cancer. Gastroenterology, 1993, 104, 910-915.	1.3	53
165	Autoradiographic and flow-cytometric assessment of cell proliferation in primary colorectal cancer: Relationship to dna ploidy and clinico-pathological features. International Journal of Cancer, 1992, 50, 719-723.	5.1	19
166	Cell kinetics evaluation of colorectal tumors afterin vivo administration of bromodeoxyuridine. International Journal of Cancer, 1992, 52, 856-861.	5.1	19
167	Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study. Cancer, 1992, 69, 626-635.	4.1	101
168	Decrease in plasma tryptophan after a tryptophan-free amino acid solution. A comparison between cirrhotic and control subjects. Life Sciences, 1991, 48, 409-418.	4.3	14
169	Correlation between bromodeoxyuridine labelling and ornithine decarboxylase levels in normal rectal mucosa of patients with colorectal adenoma. Cancer Letters, 1991, 59, 221-224.	7.2	12
170	Pattern of cell kinetics in colorectal mucosa of patients with different types of adenomatous polyps of the large bowel. Cancer, 1991, 68, 873-878.	4.1	34
171	Evidence for the existence of different types of large bowel tumor: Suggestions from the clinical data of a population-based registry. Journal of Surgical Oncology, 1990, 44, 35-43.	1.7	52
172	Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer, 1990, 66, 2047-2051.	4.1	180
173	The influence of age on colonic epithelial cell proliferation. Cancer, 1988, 62, 2373-2377.	4.1	85
174	Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Digestive Diseases and Sciences, 1988, 33, 1218-1222.	2.3	47
175	Incidence and familial occurrence of colorectal cancer and polyps in a health-care district of Northern Italy. Cancer, 1987, 60, 2848-2859.	4.1	120
176	Complications following percutaneous liver biopsy. Journal of Hepatology, 1986, 2, 165-173.	3.7	1,131
177	Effect of small doses of deoxycholic acid on bile cholesterol saturation in patients with liver cirrhosis Gut, 1986, 27, 23-28.	12.1	9
178	Cholesterol esterase activity of human intestinal mucosa. Digestive Diseases and Sciences, 1985, 30, 1053-1064.	2.3	5
179	Effects of acute changes of bile acid pool composition on biliary lipid secretion Journal of Clinical Investigation, 1984, 74, 614-624.	8.2	99
180	Effect of Cicloxilic Acid on Bile Lipid Composition in Patients with Gallstones: A Multicenter Trial. Digestion, 1983, 28, 102-107.	2.3	1

#	Article	IF	CITATIONS
181	Gallstone Dissolution after 6 Months of Ursodeoxycholic Acid (UDCA): Effectiveness of Different Doses. Journal of International Medical Research, 1982, 10, 59-63.	1.0	11
182	Influence of Small-Bowel Transit Time on Dietary Cholesterol Absorption in Human Beings. New England Journal of Medicine, 1982, 307, 102-103.	27.0	55
183	Cholesterol absorption in cirrhosis: The role of total and individual bile acid pool size. Gastroenterology, 1981, 80, 1428-1437.	1.3	21
184	Effect of the selective expansion of cholic acid pool on bile lipid composition: Possible mechanism of bile acid induced biliary cholesterol desaturation. Gastroenterology, 1981, 81, 539-546.	1.3	39
185	Chronic active hepatitis. Digestive Diseases and Sciences, 1981, 26, 957-958.	2.3	2
186	Cholesterol absorption during bile acid feeding. Gastroenterology, 1980, 78, 214-219.	1.3	97
187	Bile acid feeding and hepatic sterol metabolism: Effect of deoxycholic acid. Gastroenterology, 1980, 79, 637-641.	1.3	35
188	The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption. Gastroenterology, 1979, 77, 223-230.	1.3	65
189	Bile lipid composition and bile acid pool size in diabetes. The American Journal of Digestive Diseases, 1978, 23, 710-716.	0.9	67